Nkarta Announces September 2020 Virtual Investor Conference Schedule

Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX) will participate in the Cantor Virtual Global Healthcare Conference on September 15, 2020, with a fireside chat presentation scheduled for 2:00 p.m. ET. The event will feature a live audio webcast available on Nkarta's website, with a replay archived for approximately four weeks.

Nkarta is focused on developing engineered natural killer (NK) cell therapies for cancer, utilizing a proprietary platform for efficient manufacturing and cell engineering aimed at enhancing tumor targeting and persistence.

Positive

• Participation in a notable investor conference could enhance visibility and investor interest.
• Focus on engineered NK cell therapies positions Nkarta in a promising area of oncology.

Negative

• None.

News Market Reaction – NKTX

+6.91%

+6.91% Session move

In the trading session that priced this news, NKTX gained 6.91%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference:

Cantor Virtual Global Healthcare Conference
Date: Tuesday, September 15, 2020
Fireside chat presentation: 2:00 p.m. ET

A live audio webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com. A replay of the webcast will be archived on the website for approximately four weeks.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com

FAQ

When is Nkarta's presentation at the Cantor Virtual Global Healthcare Conference?

Nkarta's presentation is on September 15, 2020, at 2:00 p.m. ET.

Where can I watch Nkarta's conference presentation?

A live audio webcast of Nkarta's presentation will be available on their website.

What is Nkarta's focus in biotechnology?

Nkarta is developing allogeneic natural killer (NK) cell therapies aimed at treating cancer.

How long will the replay of Nkarta's conference presentation be available?

The replay of the webcast will be archived on Nkarta's website for approximately four weeks.